Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design
Susan E. Krown(Memorial Sloan Kettering Cancer Center), Henry Koon(Case Western Reserve University), Jeannette Y. Lee(University of Arkansas at Little Rock), Barbara Fingleton(Vanderbilt University), Merrill J. Egorin(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|733
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707